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1031-199 Rapamycin Inhibits Expression of Minichromosome 
Maintenance Proteins in Vascular Smooth Muscle Cells 
Dennis Bruemmer, Fen Yin, Joey Liu, Eckart Fleck, Andre van Herie, Ronald Law, 
University of California, Los Angeles, CA, German Heart Institute, Berlin, Germany 
Background: Rapamycin inhibits proliferation of vascular smooth muscle cells (VSMC) 
and local delivery of rapamycin from polymer-coated stents represents a novel therapeu- 
tic strategy for preventing postangioplasty restonsis. The molecular mechanims by which 
rapamycin exerts its antiproliferative activity involves an inhibition of Gi +S phase transi- 
tion. However, the effects of rapamycin on S phase and DNA replication remain to be 
investigated. In the present study the effect of rapamycin on minichromosome mainte- 
nance (MCM) proteins 6 and 7, two proteins essential for initiation of DNA’replication. 
was investigated in rat aortic VSMC. 
Methods and results: Rapamycin substantially inhibited mitogen-induced MCM6 and 
MCM7 mRNA (68.2 f 5.6 %. 71.2 f 6.9 % inhibition vs. IO % FBS after 12 hours treat- 
ment with 100 nM rapamycin, n=3, ~~0.05) and protein (61 .l * 8.3 %. 52.7 f 6.0 % inhi- 
bition vs. 10 % FBS after 24 hours treatment with 100 nM rapamycin, n=3, ~~0.05) 
expression in a dose-dependent fashion. Transient transfection experiments revealed 
that rapamycin inhibited MCM6 and MCM7 promotor activity (58.3 f 6.8 %, 67.1 f 8.4 % 
inhibition vs. 10% FBS after 48 hours treatment with 100 nM rapamycin, n=3, ~~0.05) 
implicating a transcriptional mechanism. MCM6 and MCM7 transcriptional activation is 
regulated by E2F and activity of a luciferase reporter plasmid driven by four E2F ele- 
ments was also strongly inhibited by rapamycin (63.1 f 7.3 % inhibition after 48 hours, 
n=3. p<O.O5). The inhibitory effect of rapamycin on MCM8 and MCM7 was reversed by 
adenoviral mediated overexpression of E2F, indicating that their downregulation by rapa- 
mycin involves an E2F-dependent mechanism. 
Conclusion: These observation suggest that rapamycin inhibits MCMG and MCM7 
expression by blocking EZF function which may contribute importantly to the inhibition of 
VSMC DNA synthesis by rapamycin. 
1031-200 Site Specific Systemic Delfvery of Rapamycin With 
Perfluorobutane Gas Microbubble Carrier Reduced 
Neointimal Formation in the Porcine Coronary 
Restenosis Model 
Nicholas N. Kipshidze, Ahmadian Yazdi. Fermin Tio, Rufus Seaborn, Tom Porter, Milena 
G. Adamian. Fena Xie. Georae Danaas. Martin B. Leon. Jeffrev W. Moses. Patrick 
Iversen, Lenox Hill Heart and Vascular Institute, Cardiovascular Research Foundation, 
New York, NY, Cardiovascular Research Institute, Washington, DC 
Hypothesis: Stent based delivery of Rapamycin was shown to inhibit intimal hyperplasia 
in animal models and to eliminate restenosis in clinical trials. However the potential for 
long-term adverse effects secondary to the polymeric coatings has been subject of con- 
cern. It was previously demonstrated that perfluorobutane gas panicles adhere to injured 
arteries. Additionally perfluorobutane gas enhances cell entry for drugs on the surface of 
bubbles that come into contact with denuded vessel surfaces. The purpose of this study 
was to investigate the effects of PGMC-based delivery of Rapamycin on expression of 
p21 and p27 in vascular tissue and restenosis in porcine arteries after stent implantation. 
Methods: Seven pigs underwent stent implantation (3 stentslanimal). Four pigs received 
IV injection of PGMC and 2mg of Rapamycin. Two served as control. Four hours later, 3 
pigs were sacrificed and stented segments were analyzed by HPLC and western blot. In 
chronic experiments, 4 pigs (12 stent sites) were sacrificed at 28 days. 
Results: HPLC analysis of plasma samples of treated animals showed mmimal pres- 
ence of Rapamycin, whereas HPLC of the treated arteries demonstrated high concentra- 
tion of the drug (190-280 mcg). Western blot analysis of the stented vessels 
demonstrated over-expression of p21 and ~27. Morphometry showed that the neointimal 
was significantly reduced 40% in the Rapamyciwbubble group compared with control 
(2.84 eO.84 vs. 4.77 *I .71 mm2 respectively, peO.05). Conclusion: In this animal model 
site-specific systemic delivery of Rapamycin using PGMC resulted in over-expression of 
p-21 and p-27 in the stented segments and significantly inhibited neointimal formation. 
1031-201 Local Delivery of lrinotecan With Drug-Eluting Stents 
Inhibits Neointimal Proliferation In 
Hypercholesterolemic Rabbits 
Daniel H. Bermcal, German E. Gonzalez, Celina Morales, Mauricio G. Cohen, Ricardo J. 
Gelpi, Liliana R. Grinfeld, Hospital Italian0 de Buenos Aires, Buenos Aires, Argentina 
Background: Recent studies have shown that local delivery of cytostatic or antineoplas- 
tic drugs inhibits neointimal growth after stent implantation. lrinotecan inhibits DNA repli- 
cation. 
Objective: To assess the effect of irinotecan-eluting stents on neointimal growth in the 
aorta of hypercholesterolemic rabbits. 
Methods: Phosphorylcholine (PC) coated stents were deployed in the aorta of 30 hyper- 
cholesterolemic New Zealand rabbits. All stents had a diameter of 3.0mm and a length of 
15mm. Group 1 (n=lO), the control group, received bare stents, group 2 (n=lO) received 
a PC-coated stent with low-dose idnotecan (46.5~) and group 3 (n=lO) received a PC- 
coated stent with high-dose irinotecan (129mg). All rabbits were sacrificed by the sec- 
ond month after stent-implantation. Morphometric analysis was performed to assess 
neointimal growth thickness (NT). A semi-quantitative injury score (from 0 to 3) was used 
to analyze necrosis (N), macrophages (M), edema (E), hemorrhage (H), and fibrin con- 
tent(F). in the stented segments. 
Resutts: In 3 cases the procedure was unsuccessful and 4 rabbits died before complet- 
ing the e-month follow-up period. These cases were excluded. No differences were 
observed in terms of injury score. The following table displays the study results.( ‘PC 
0.05 vs Group 1). 
NT NM EHF 
Group1 (n=7) 207.9+31.6 0 1.14r0.15 0 0 0.50r0.20 
GroupP(n.7) 156.3k36.5 0 0.75r0.29 0 0 0.75kO.29 
Group3 (n=9) 113.4+17.2’ 0 1.29+0.20 0 0 1.00~0.00’ 
Conclusions: PC-coated stems loaded with high-dose innotecan inhibit neointimal thick- 
ening III the abdominal aorta of hypercholesterolemic rabbits. This effect was not accom- 
panted by cellular injury. 
1031-202 Active Glycogen Synthase Kinase-3 Gene Transfer 
Inhibits Smooth Muscle Proliferation and Neointima 
Formation After Balloon Injury in Rats 
Kvuna-Woo Park, Han-MO Yang, In-Ho Chae, Hyo-Soo Kim, Kenneth Walsh, Clinical 
Research Center, Seoul National University Hospital, Seoul, South Korea, Whitaker 
Cardiovascular Institute, Boston University School of Medicine, Boston, MA 
Background: Glycogen Synthase Kinase(GSK)-3 is a crucial factor in many cellular sig- 
nailing pathways and plays an important role in protein synthesis, cell proliferation, differ- 
entiation, microtubule dynamics. cell motility, and survival. We recently reported the 
antiproliferative and antimigratory effects of active GSK-Z@ gene transfer in human aortic 
smooth muscle cells in vitro. 
Methods: To investigate the effect of active GSK-38 gene transfer on the formation of 
neointima after balloon injury in rats in viva we delivered adenoviral vectors expressing 
the constitutively active form of GSK-B3 (GSK-SSA: 9rh serine switched to alanine) or a 
control gene into rat carotid arterial segments after balloon injury with a 2F Forgarty cath- 
eter. Viral infusion mixtures containing dxlO$fu of virus diluted to a total volume of 
1 OOuL were incubated in the arterial lumen for 20minutes and the effects of gene delivery 
were evaluated 3 days and 2 weeks after gene delivery with morphometry and immuno- 
histochemical staining. 
Results: There were no significant differences in intimal, medial, and lumen areas at 3 
days after the procedure. However, two weeks after gene delivery, the active GSK-38 
gene transfer resulted in a significantly lower intimafmedia (I/M) ratio (0.29kO.06 vs 
0.86t0.09, pcO.01) and a greater lumen area (0.41+0.02 vs 0.31~0.01mm’, ~~0.01) 
compared to the control gene transfected group. This was due to a significant reduction 
in intimal area (0.05*0.01 vs 0.15+0.02mmz, p<O.Ol) while the medial area was similar 
(0.17+0.01 vs 0.18iO.01 mm’, p=O.21). Proliferating cell nuclear antigen (PCNA) positive 
cells were significantly reduced in the neointima at 14 days in the active GSK-33 gene 
transferred group (2.97r0.29 vs 5.71+0.50%, p<O.Ol). 
Conclusion: In viva delivery of the active GSK-8l gene inhibits smooth muscle prolifera- 
tion and neointima formation after balloon injury in rats, and may be a future target for 
gene therapy to inhibit restenosrs after balloon angioplasty. 
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1051-187 The Smoker’s Paradox in Patients Undergoing 
Percutaneous Coronary Intervention: A Report From 
the Dynamic Registry 
Daniel Wachsman, Faith Seizer, Katherine M. Detre, David 0. Williams, Alice K. Jacobs, 
Boston Medical Center, Boston, MA, University of Pittsburgh, Pittsburgh, PA 
Background: Despite the known detrimental effects of smoking on the incidence of and 
mortality from CAD, a paradoxical beneficial effect has been observed in smokers with 
myocardial infarction (Ml). Methods: To determine whether the smoker’s paradox exists 
for patients undergoing percutaneous coronary intervention (PCIJ. we evaluated 4,389 
patients in the 1997-99 NHLBI Dynamic Registries, of whom 1,138 were current (CSM). 
1,762 former (FSM) and 1,469 never (NSM) smokers. All comparisons were made to the 
NSM group. Results: CSM and FSM patients were significantly (all pcO.001) younger 
(55.9 vs 64.4 vs 65.7 yrs) and less often female (31.7 vs 26.3 vs 50.0%) in comparison to 
NSM. Among CSM, the prevalence of diabetes (20.2 vs 33.7%) hypertension (53.7 vs 
66.0%) CHF (5.6 vs 11.3%). prior PCI (20.5 v’s 29.1%). and prior CABG (7.6 vs 17.4%) 
was lower whereas the prevalence of pulmonary disease (10.3 vs 4.0%) and presenta- 
tion with an Ml (33.5 vs 20.5%) was higher compared to NSM (all p<O.OOl). Angiographic 
differences also existed, with CSM significantly (all p<O.OOl) more likely to present with 
single-vessel disease (47.9 vs 42.2%) lesion location in the right coronary artery (36.7 v’s 
30.5%) and to have vessels that were more thrombotic (24.7 vs 18.3%), ulcerated (13.9 
vs 10.5%). occluded (17.3 vs 11.8%) and collateralized (16.0 vs 12.4%) in COmparisOn 
to NSM. Despite similar procedural success rates, in-hospital mortality was significantly 
lower in CSM and FSM (0.8 and 1 .O vs 2.0%, both p&05) than in NSM. However, after 
adjustment for baseline differences, the risk of mortality did not differ from NSM (CSM vs 
NSM Odds Ratio 0.58, 95% Cl 0.24, 1.39 and FSM vs NSM Odds Ratio 0.61, 95% Cl 
0.31, 1.19). At one year, mortality (3.7 vs 5.7%) and repeat revascularization (18.5 vs 
20.6%) rates were significantly (~~0.05) lower in CSM compared to NSM patients but 
again, after adjustment, the relative risk of death, Ml or repeat revasculanzation was sim- 
